• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

    16.08 -0.11 (-0.68%)
    Delayed Quote Updated: 1:38 PM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 381,461
    Open 16.19
    Bid (Size) 16.07 (200)
    Ask (Size) 16.08 (200)
    Prev. Close 16.19
    Today's Range 15.92 - 16.23
    52wk Range 10.90 - 19.25
    Shares Outstanding 128,395,927
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Aurinia Settles Patent Litigation with Teva
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire

    Performance

    YTD
    +4.8%
    +4.8%
    1 Month
    -0.2%
    -0.2%
    3 Month
    +1.8%
    +1.8%
    6 Month
    +3.9%
    +3.9%
    1 Year
    +45.5%
    +45.5%

    More News

    Read More
    News headline image
    Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum Rating ↗
    Via Chartmill
    AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Screens Strong on Minervini Trend Template and High Growth Momentum ↗
    Via Chartmill
    AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH): A High-Growth Momentum and Technical Trend Case Study ↗
    Via Chartmill
    Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Passes Key Growth Screener from "The Little Book That Makes You Rich" ↗
    Via Chartmill
    Aurinia Pharmaceuticals (NASDAQ:AUPH) Beats Q4 2025 Estimates and Provides 2026 Guidance ↗
    Via Chartmill
    News headline image
    Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
    Via Newsfile
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Aurinia Announces Management Transition
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗
    Via Stocktwits
    News headline image
    Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
    Via The Motley Fool
    News headline image
    AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Passes Louis Navellier's Strict Growth Stock Screen ↗
    Via Chartmill
    News headline image
    Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    A Peek at Aurinia Pharmaceuticals's Future Earnings ↗
    Via Benzinga
    News headline image
    FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse ↗
    Via Benzinga
    News headline image
    Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
    From Aurinia Pharmaceuticals Inc.
    Via Business Wire
    News headline image
    FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ ↗
    Via Stocktwits
    Topics Lawsuit

    Frequently Asked Questions

    Is Aurinia Pharmaceuticals Inc - Common Shares publicly traded?
    Yes, Aurinia Pharmaceuticals Inc - Common Shares is publicly traded.
    What exchange does Aurinia Pharmaceuticals Inc - Common Shares trade on?
    Aurinia Pharmaceuticals Inc - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares?
    The ticker symbol for Aurinia Pharmaceuticals Inc - Common Shares is AUPH on the Nasdaq Stock Market
    What is the current price of Aurinia Pharmaceuticals Inc - Common Shares?
    The current price of Aurinia Pharmaceuticals Inc - Common Shares is 16.08
    When was Aurinia Pharmaceuticals Inc - Common Shares last traded?
    The last trade of Aurinia Pharmaceuticals Inc - Common Shares was at 10/01/26 01:38 PM ET
    What is the market capitalization of Aurinia Pharmaceuticals Inc - Common Shares?
    The market capitalization of Aurinia Pharmaceuticals Inc - Common Shares is 2.06B
    How many shares of Aurinia Pharmaceuticals Inc - Common Shares are outstanding?
    Aurinia Pharmaceuticals Inc - Common Shares has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.